Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
OwnerAndré Delacourte, Nicolas Sergeantinventors
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated with β-amyloid formation and/or aggregation.
Claims14
-25. (canceled)
A method for determining, in a patient, the susceptibility to a disease associated with β-amyloid formation and/or aggregation, for determining, the risk of developing a disease associated with β-amyloid formation and/or aggregation, for screening of the clearance of β-amyloid deposition, and/or for predicting the level of β-amyloid burden, said method comprising:
- (a) determining, in a sample of brain extract or cerebrospinal fluid obtained from said patient, the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof, the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof, or the amount of antibody or reactive T-cells specific for said β-amyloid variant or N-terminal fragment thereof or said APP soluble fragment or C-terminal fragment thereof;
- (b) comparing the amount determined in step (a) with the amount of said N-terminal truncated and/or post-translationally modified β-amyloid variant or an N-terminal fragment thereof, the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof, or the amount of antibody or reactive T-cells specific for said β-amyloid variant or an N-terminal fragment thereof or said APP soluble fragment or a C-terminal fragment thereof in a control sample obtained from a control population known not to suffer said disease;
- and
- (c) concluding, from the comparison in step (b), whether the patient is susceptible to a disease associated with β-amyloid formation and/or aggregation, whether the patient is at risk of developing a disease associated with β-amyloid formation and/or aggregation, whether the β-amyloid deposition in the patient is cleared, or what the level of β-amyloid burden is in said patient.
-28. (canceled)
Dependencies are inferred from the claim text.